Volunteer for NIAID-funded clinical studies related to antimicrobial (drug) resistance on ClinicalTrials.gov.
Microbes, collectively, include bacteria, viruses, fungi, and parasites. For the past 70 years, antimicrobial drugs, such as antibiotics, have been successfully used to treat patients with bacterial and infectious diseases. Over time, however, many infectious organisms have adapted to the drugs designed to kill them, making the products less effective. To address this growing problem, NIAID is funding and conducting research on many aspects of antimicrobial (drug) resistance, including basic research on how microbes develop resistance, new and faster diagnostics, and clinical trials designed to find new vaccines and treatments effective against drug-resistant microbes.
Media Availability: NIH Launches Phase I Clinical Trial of Novel Drug to Treat Clostridium difficile Infection—July 9, 2014
Bulletin: NIH Funding Opportunity Focuses on Diagnostics for Hospital-Based Antibacterial-Resistant Infections —April 4, 2014
Media Availability: Fauci: Robust Research Efforts Needed to Address Ongoing, Global Challenge of Antimicrobial Resistance—March 20, 2014
NIAID's Antibacterial Resistance Program - Current Status and Future Directions 2014 (PDF)
Last Updated July 18, 2014